In a natural response to injury or infection, the body produces chemicals that trigger the immune system to release antibodies and proteins plus increase blood flow to the afflicted area, which aids healing and produces inflammation. However, the immune system and the inflammatory processes have pernicious aspects far removed from beneficial healing. In fact, inflammation has been directly linked to a wide variety of physical and mental health maladies. Inflammation is also a symptom of infectious diseases, implicated in noninfectious diseases, and new findings show a causal relationship with postsurgical trauma. Inflammatory diseases are recognized as the most significant cause of death in the world, with more than 50% of all deaths attributed to inflammation-related diseases. The recognition of the connection between inflammation and disease sparked a flurry of biotech research and a new generation of drug development to treat previously untreatable disorders. World renowned scientists that now lead 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Profile) pioneered the research and development of one of the first anti-inflammatory therapeutics to ever reach market, and today these drugs generate multiple billions of dollars in annual sales. Critical to creation of some the most important and profitable drugs ever on the market, the 180 team is in hot pursuit of new anti-inflammatory blockbusters with active programs in both preclinical and clinical studies. The world’s largest and most broadly based health-care company, Johnson & Johnson (NYSE: JNJ)owns Remicade (infliximab), a blockbuster several times over with approved use in a range of inflammatory diseases. The founders of 180 Life Sciences discovered the anti-TNF (tumor necrosis factor) drug class that led to the development of Remicade and to a $4.9 billion merger between JNJ and Centocor Biotech. AbbVie Inc. (NYSE: ABBV) owns Humira, an anti-TNF therapeutic and top-selling drug in the world. The scientists at 180 Life Sciences licensed the anti-TNF technology in development of Humira. One of the world’s leading biotech’s, Amgen Inc. (NASDAQ: AMGN), bought Celgene’s blockbuster anti-inflammatory drug Otezla in 2019 for $13.4 billion in cash, and Eli Lilly (NYSE: LLY) recently announced a deal for Rigel Pharmaceuticals’ autoimmune and inflammatory diseases treatment for $960 million. In addition to delivering much-needed relief for previously untreatable maladies, eye-popping sales and king-sized acquisitions are likely to accelerate in the anti-inflammatory space, as more new and highly effective drugs come to market.

Watch Now:
Share | Download